Premier Biotech Acquires National Test Systems

Premier Biotech, a portfolio company of Align Capital Partners, has acquired National Test Systems (NTS), a provider of rapid point-of-care drug screening supplies and services that serves more than 1,500 facilities across the United States. The acquisition expands Premier's point-of-care testing capabilities (including oral fluid testing) and deepens its presence in government and behavioral health end markets; NTS CEO Andrew Panico will remain involved to support the transition.